Inclusion Criteria:

- Bilirubin =< 1.5 times upper limit of normal (ULN)

- AST/ALT =< 2.5 times ULN

- Creatinine =< 1.5 times ULN OR creatinine clearance >= 60 mL/min

- Proteinuria =< 1+ by dipstick OR urine protein < 500 mg by 24-hour urine analysis

- No serious or nonhealing wound, ulcer, or bone fracture

- No abdominal fistula, gastrointestinal perforation, bowel obstruction, or
intra-abdominal abscess within the past 28 days

- At least 4 weeks since prior major surgical procedure or open biopsy

- Histologically or cytologically confirmed colorectal cancer

- No significant traumatic injury within the past 28 days

- Recovered from prior therapy

- Measurable disease, defined as >= 1 lesion that can be accurately measured in >= 1
dimension as >= 20 mm by conventional techniques or as >= 10 mm by spiral CT scan

- No prior surgery, radiation therapy, or radiofrequency ablation to the measurable
lesion

- Has received >= 1 prior systemic chemotherapy for metastatic disease AND has
documented radiological or clinical progression after the most recent therapy

- No CNS disease, including primary brain tumor or brain metastasis

- Life expectancy >= 3 months

- ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

- No clinically significant cardiovascular disease, including, but not limited to, any
of the following: Peripheral vascular disease within the past 6 months (i.e.,
limiting activities of daily living or the presence of resting pain), Deep vein
thrombosis, pulmonary embolism, or other thromboembolic event within the past 6
months, Coronary artery bypass graft within the past 6 months, OR;

- OR; Unstable angina pectoris or myocardial infarction within the past 6 months, New
York Heart Association class III or IV congestive heart failure, Serious cardiac
arrhythmia requiring medication, Uncontrolled hypertension, defined as blood pressure
(BP) > 150/100 mm Hg OR systolic BP > 180 mm Hg (if diastolic BP < 90 mm Hg) within
the past 3 months

- No evidence of bleeding diathesis or coagulopathy

- No uncontrolled intercurrent illness including, but not limited to, any of the
following: Ongoing or active infection, Psychiatric illness or social situation that
would limit compliance with study requirements

- No active bleeding or pathological condition that carries a high risk of bleeding
(e.g., evidence of tumor invading major vessels by CT scan or known varices)

- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant
human antibodies

- No history of allergic reactions to compounds of similar chemical or biologic
composition to VEGF Trap or other agents used in this study

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for >= 6 months after
completion of study treatment

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C),
prior thymidylate synthetase inhibitor (e.g., fluorouracil or capecitabine) allowed
as a radiosensitizer

- At least 4 weeks since prior radiation therapy of local disease, disease progression
must be documented afterwards

- At least 4 weeks since other prior anticancer agents

- At least 4 weeks since prior thrombolytic agents

- At least 7 days since prior core biopsy

- No prior antiangiogenic therapy (e.g., vascular endothelial growth factor tyrosine
kinase inhibitor) other than bevacizumab

- Prior anti-epidermal growth factor receptor inhibitors allowed

- No other concurrent investigational agents

- No concurrent antiretroviral therapy for HIV-positive patients

- No concurrent major surgery

- Concurrent full-dose anticoagulants (e.g., warfarin or low molecular weight heparin)
allowed provided dose is stable

- WBC >= 3,000/mm^3

- Absolute neutrophil count >= 1,500/mm^3

- Platelet count >= 75,000/mm^3

- INR =< 1.5 (=< 3 if on full-dose warfarin)

- Metastatic disease

- Concurrent antihypertensive medications allowed, unless dose and/or quantity has been
increased within the past 2 weeks